{"id":"abp-710","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Serious infections"},{"rate":null,"effect":"Tuberculosis reactivation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABP 710 is designed as a biosimilar to Humira (adalimumab), a fully human monoclonal antibody that binds and neutralizes TNF-α, a key inflammatory cytokine. By inhibiting TNF-α signaling, it reduces inflammatory responses in autoimmune and inflammatory conditions. As a biosimilar, ABP 710 is manufactured through recombinant DNA technology and is intended to have comparable efficacy and safety to the reference product.","oneSentence":"ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:04.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":95},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT07237516","phase":"","title":"Zymfentra (Infliximab-dyyb) REal World Cohort STudy","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-20","conditions":"Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis","enrollment":200},{"nctId":"NCT07472309","phase":"","title":"Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-06-06","conditions":"Ulcerative Colitis (UC), Acute Severe Ulcerative Colitis, Upadacitinib","enrollment":81},{"nctId":"NCT07470502","phase":"NA","title":"MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-02-13","conditions":"IBD (Inflammatory Bowel Disease)","enrollment":15},{"nctId":"NCT00606346","phase":"","title":"A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Biotech, Inc.","startDate":"2007-05-31","conditions":"Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis","enrollment":4970},{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1056},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT04974099","phase":"PHASE2, PHASE3","title":"Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-10-01","conditions":"Crohn Disease","enrollment":6},{"nctId":"NCT04835506","phase":"PHASE4","title":"Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-11-01","conditions":"Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":124},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT07424040","phase":"NA","title":"The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-01","conditions":"Crohn's Diseases, Crohn's Disease in Pediatric Patient","enrollment":154},{"nctId":"NCT07417696","phase":"PHASE4","title":"Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Disease","enrollment":400},{"nctId":"NCT03907631","phase":"","title":"Multi-centre Acute Severe Ulcerative Colitis Prospective Cohort Study (Elevate ASUC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2019-10-18","conditions":"Severe Ulcerative Colitis","enrollment":189},{"nctId":"NCT07415473","phase":"PHASE4","title":"Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Diseases","enrollment":400},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Ulcerative Colitis","enrollment":4000},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05689879","phase":"PHASE3","title":"Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-23","conditions":"Sarcoidosis","enrollment":90},{"nctId":"NCT07385131","phase":"","title":"Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-08","conditions":"Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis","enrollment":300},{"nctId":"NCT04305145","phase":"PHASE2","title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-31","conditions":"Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III","enrollment":42},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT07344428","phase":"NA","title":"Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-02-01","conditions":"Crohn's Disease；Mucosal Healing；Dietary Intervention","enrollment":185},{"nctId":"NCT02998398","phase":"","title":"Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-10","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease","enrollment":262},{"nctId":"NCT01917721","phase":"PHASE2","title":"Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hawaii Pacific Health","startDate":"2013-10","conditions":"Kawasaki Disease, Coronary Aneurysm","enrollment":50},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT07314606","phase":"NA","title":"Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12-15","conditions":"Crohn Disease (CD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease","enrollment":140},{"nctId":"NCT01680159","phase":"PHASE3","title":"A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-07","conditions":"Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized)","enrollment":51},{"nctId":"NCT00691028","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":327},{"nctId":"NCT01585155","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-02","conditions":"Pediatric Ulcerative Colitis","enrollment":21},{"nctId":"NCT01580670","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-03","conditions":"Pediatric Crohn's Disease","enrollment":14},{"nctId":"NCT00805766","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":39},{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT03885037","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Rheumatoid Arthritis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-20","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT06381518","phase":"NA","title":"Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2024-03-12","conditions":"IBD, Infliximab, Crohn Disease","enrollment":38},{"nctId":"NCT06646016","phase":"PHASE2","title":"EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis","status":"WITHDRAWN","sponsor":"Therakos LLC","startDate":"2025-12-15","conditions":"Immune-related Colitis","enrollment":""},{"nctId":"NCT07297069","phase":"PHASE2","title":"Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-01-01","conditions":"Acute Severe Ulcerative Colitis","enrollment":60},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT01630850","phase":"NA","title":"Islet Transplantation in Patients With \"Brittle\" Type I Diabetes","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT07263477","phase":"","title":"A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease (CD)","enrollment":900},{"nctId":"NCT07257068","phase":"NA","title":"Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-04-14","conditions":"Checkpoint Inhibitor, Pilot Study, Diabetes Melletus","enrollment":14},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT04898231","phase":"PHASE2, PHASE3","title":"MIS-C Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-22","conditions":"Multisystem Inflammatory Syndrome-Children","enrollment":73},{"nctId":"NCT05781152","phase":"PHASE4","title":"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","status":"RECRUITING","sponsor":"Connecticut Children's Medical Center","startDate":"2023-06-10","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT07176754","phase":"NA","title":"TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-10-01","conditions":"Cardiac Arrest (CA), Post Cardiac Arrest Syndrome","enrollment":208},{"nctId":"NCT05424926","phase":"","title":"Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-24","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":22},{"nctId":"NCT03684278","phase":"PHASE2","title":"Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2019-05-01","conditions":"Acute Pancreatitis","enrollment":290},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07120152","phase":"","title":"A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Erwin Dreesen","startDate":"2025-09-01","conditions":"IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis","enrollment":439},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":"Anoperineal Lesions, Crohn's Disease Relapse","enrollment":52},{"nctId":"NCT07149441","phase":"NA","title":"Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-08-01","conditions":"Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation","enrollment":94},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07123207","phase":"NA","title":"Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-04","conditions":"Mild to Severe Crohns Disease","enrollment":24},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT02638701","phase":"PHASE1, PHASE2","title":"Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-01","conditions":"Aneurysm, Stroke, Vasculitis","enrollment":8},{"nctId":"NCT00463580","phase":"PHASE4","title":"A Study of Infliximab for Treatment Resistant Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-12","conditions":"Depression","enrollment":60},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT03679546","phase":"PHASE4","title":"EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-01-04","conditions":"Ulcerative Colitis","enrollment":151},{"nctId":"NCT06660693","phase":"PHASE3","title":"Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-16","conditions":"Colitis, Ulcerative","enrollment":134},{"nctId":"NCT03885089","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Psoriasis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-21","conditions":"Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis","enrollment":10},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT05362630","phase":"","title":"Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2022-04-01","conditions":"Graft Versus Host Disease, Acute, Hematopoietic Stem Cell Transplantation","enrollment":28},{"nctId":"NCT05796245","phase":"","title":"A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-01","conditions":"Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease","enrollment":2207},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT06998797","phase":"","title":"Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-01","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT06995170","phase":"","title":"Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-01-01","conditions":"Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease","enrollment":146},{"nctId":"NCT05906576","phase":"PHASE4","title":"Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients","status":"RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-09-21","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT03765450","phase":"","title":"Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2018-12-21","conditions":"Ulcerative Colitis","enrollment":18},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":172},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT06136546","phase":"PHASE2","title":"Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-01-23","conditions":"Depressive Disorder, Major, Inflammation","enrollment":100},{"nctId":"NCT06954311","phase":"","title":"Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Medical University Innsbruck","startDate":"2025-02-17","conditions":"Ulcerative Colitis (UC), IBD-unclassified (IBD-U)","enrollment":120},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT04312659","phase":"","title":"A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson (China) Investment Ltd.","startDate":"2020-07-15","conditions":"Crohn Disease","enrollment":38},{"nctId":"NCT02229344","phase":"","title":"Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2014-07-01","conditions":"Colitis, Ulcerative","enrollment":368},{"nctId":"NCT00741793","phase":"","title":"Biologic Treatment Registry Across Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2002-02-12","conditions":"Arthritis, Rheumatoid, Spondyloarthritis, Axial, Arthritis, Psoriatic","enrollment":2821},{"nctId":"NCT05599347","phase":"PHASE2","title":"Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-04-24","conditions":"Crohn's Disease Relapse, Biological Substance; Adverse Effect","enrollment":180},{"nctId":"NCT05722353","phase":"NA","title":"IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-13","conditions":"Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT03884439","phase":"","title":"Infliximab Biosimilar \"Pfizer\" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-18","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":428},{"nctId":"NCT05313620","phase":"PHASE4","title":"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2022-04-01","conditions":"Ulcerative Colitis, Thromboembolism","enrollment":30},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT04331639","phase":"","title":"High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2020-11-01","conditions":"Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis","enrollment":50},{"nctId":"NCT06758024","phase":"NA","title":"PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-01-24","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":72},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT06839820","phase":"NA","title":"Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2025-02-01","conditions":"Infliximab, Infusion, IBD (Inflammatory Bowel Disease)","enrollment":60},{"nctId":"NCT06849739","phase":"","title":"Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-03-02","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABP 710","genericName":"ABP 710","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}